Press Releases – NASDAQ (US) Website
beigene
IR Menu

Press Releases

May 04, 2023
BeiGene Reports First Quarter 2023 Financial Results and Corporate Developments    read more...
Apr 26, 2023
BeiGene to Highlight Broad Oncology Portfolio at the 2023 ASCO Annual Meeting    read more...
Apr 25, 2023
BeiGene Announces Goals Focused on Sustainable Growth and Workforce Diversity in New ESG Report    read more...
Apr 20, 2023
BeiGene Announces Positive Phase 3 Tislelizumab Trial in Advanced Gastric or Gastroesophageal Junction Adenocarcinoma    read more...
Apr 17, 2023
BeiGene and SpringWorks Present Clinical Data on Lifirafenib, in Combination with Mirdametinib, in Patients with Advanced or Refractory Solid Tumors with MAPK Pathway Aberrations at the American Association for Cancer Research Annual Meeting 2023    read more...
Apr 17, 2023
MapKure, BeiGene and SpringWorks Present Clinical Data on BGB-3245, a Selective Next-Generation B-RAF Inhibitor, in Adult Patients with Advanced or Refractory Solid Tumors at the American Association for Cancer Research Annual Meeting 2023    read more...
Apr 13, 2023
BeiGene Expands Presence in Latin America With Opening of Brazil Office    read more...
Mar 30, 2023
BeiGene Appoints Julius Pryor III as First Global Head of Diversity and Health Equity    read more...
Mar 21, 2023
BeiGene Enters New Phase to Expand US Manufacturing and R&D Footprint in New Jersey    read more...
Feb 27, 2023
BeiGene Reports Fourth Quarter and Full Year 2022 Financial Results    read more...
Feb 24, 2023
BeiGene to Present at Cowen’s 43rd Annual Healthcare Conference    read more...
Feb 24, 2023
BeiGene Receives 10th Approval for PD-1 Inhibitor Tislelizumab in China    read more...
Feb 03, 2023
New Talk About It Resources Aim to Accelerate Integration of Mental Health into Quality Cancer Care    read more...
Feb 01, 2023
BeiGene to Present at Upcoming Investor Conferences    read more...
Jan 19, 2023
BRUKINSA® Approved in the U.S. for Chronic Lymphocytic Leukemia    read more...
Jan 19, 2023
BRUKINSA® (zanubrutinib) Receives Marketing Authorization for Chronic Lymphocytic Leukemia (CLL) and Marginal Zone Lymphoma (MZL) in Great Britain by MHRA    read more...
Jan 18, 2023
BeiGene Announces Expansion of Coverage on China’s National Reimbursement Drug List    read more...
Jan 17, 2023
BeiGene Presents New Research from Tislelizumab Global Development Program at 2023 ASCO Gastrointestinal Cancers Symposium    read more...
Jan 04, 2023
BeiGene to Present at the J.P. Morgan 41st Annual Healthcare Conference    read more...
Dec 30, 2022
BeiGene Announces Acceptance of 12th Regulatory Submission in China for PD-1 Inhibitor Tislelizumab    read more...